Alzheimer's Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER) cohort

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center prospective cohort will enroll 750 participants (250 cognitively normal, 250 with mild cognitive impairment, and 250 with Alzheimer's disease) and follow them annually for at least four years. At baseline and each annual visit participants will undergo multimodal 3T and ultra-high-field 7T MRI (including hydrogen-1 and sodium-23 sequences), blood biomarker sampling, genotyping, and standardized cognitive assessments. Structural, functional, and sodium imaging will be integrated with plasma biomarkers and genetic data and analyzed using artificial intelligence to identify early imaging signatures and model disease progression. The project also aims to create the first standardized 7T Alzheimer's neuroimaging database for the Chinese population and to address technical gaps in early detection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 55-90 years (inclusive).
* Willing and able to participate in baseline assessment and longitudinal follow-up; voluntary provision of biospecimens and personal information, and commitment to complete all follow-up visits.
* Able to undergo MRI scanning (no contraindications to MRI).
* Group-specific cognitive criteria:

CN: No subjective memory complaints beyond age expectation (confirmed by study partner); MMSE score 26-30 (inclusive; exceptions permitted for participants with \<8 years of education with principal investigator approval; CDR = 0, memory box = 0; Normal cognitive and daily functioning, no significant impairment.

MCI: Subject, partner, or physician reports subjective memory concerns; MMSE criteria same as CN group; CDR = 0.5 (memory box ≥0.5); General cognition and function relatively preserved; does not meet criteria for AD.

AD: Subject, partner, or physician reports subjective memory concerns; MMSE score \<26 (inclusive; exceptions as above); CDR = 0.5 or 1.0; Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) probable AD diagnostic criteria or 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (e.g., positive Pittsburgh compound B (PIB) and tau).

Exclusion Criteria:

* Self-reported or MRI-detected major neurological diseases other than AD: including but not limited to stroke (cerebral hemorrhage, infarction), congenital intellectual disability, intracranial tumors, epilepsy, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, severe head trauma with persistent deficits, etc.
* Severe psychiatric disorders (e.g., schizophrenia requiring medication control) or other known brain structural abnormalities.
* Significant organ failure (heart, liver, kidney, etc.), malignant tumors, or short life expectancy making completion of follow-up unlikely.
* Contraindications to MRI (e.g., claustrophobia, incompatible pacemaker, aneurysm clip, artificial heart valve, cochlear implant, or other metallic implants).
* Other clinical history or examination findings judged by investigators as potentially unsafe for MRI or follow-up.
* Use of investigational drugs within one month prior to enrollment or during the study.

Where it's running

• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using deep rTMS to improve memory in Alzheimer's Disease

  This study is testing if a new brain treatment called deep rTMS can help improve memory in people with mild to moderate Alzheimer's Disease.

  Recruiting Phase 1/2 University of California, Los Angeles · Los Angeles, California · NCT06597942

• DUVAX: a first-in-human vaccine for amyloid and tau targets in adults 40-65

  A first-in-human vaccine called DUVAX is tested in healthy adults to see if it's safe and whether it triggers an immune response against Alzheimer’s-related proteins.

  Recruiting Phase 1 Nuravax, Inc. · Miami Lakes, Florida · NCT07142278

• Cervical lymphatic bypass for treating Alzheimer's disease

  This study is testing a new surgery to see if it can help people with mild to moderate Alzheimer's disease by improving the way the brain clears out harmful proteins.

  Recruiting Changi General Hospital · Singapore · NCT06965062

• Using brain stimulation to improve memory and motivation in older adults

  This study is testing if a type of brain stimulation can help improve memory and motivation in older adults, including those showing early signs of Alzheimer's disease.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06956300

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.